Pfizer Bases Bosutinib U.S. Filing On One Single-Arm Phase II Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA accepts NDA for dual Srk and Abl inhibitor bosutinib in previously-treated Philadelphia chromosome-positive CML on a positive news day for Pfizer. Meanwhile, review in front-line CML is pending in Europe.
You may also be interested in...
Eisai Will Make “Totality Of The Evidence” Argument At FDA Panel Review Of Dacogen
Briefing documents for the Oncologic Drugs Advisory Committee’s Feb. 9 meeting suggest Eisai will argue that the totality of the data on decitabine’s efficacy and safety in elderly patients with acute myelogenous leukemia is sufficient to overcome the pivotal trial’s failure to show a statistically significant overall survival benefit in the primary analysis. In contrast, FDA’s review takes a laser-like focus on the failed primary endpoint.
Inlyta Approval Expands Pfizer Kidney Cancer Options, But With Unique Safety Profile
Second-generation VEGF inhibitor Inlyta (axitinib) gained approval based as much on its complementary safety profile as its superiority in a head-to-head comparison with Bayer/Onyx’s Nexavar .